DDInter461 DDInter308
Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts.
Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.[A215127, L14897] Although effective, these compounds are rapidly metabolized by cytidine deaminase (CDA) prior to reaching systemic circulation when administered orally, necessitating intramuscular or intravenous administration routes.[A215107, A215112, A215117, A215127] Cedazuridine is a fluorinated tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of hypomethylating agents.[A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014, and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by Astex Pharmaceuticals Inc under the name INQOVI®.
Cytarabine {u} (Compound) resembles {v} (Compound) Regadenoson
Cytarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Cytarabine {u} (Compound) binds {v} (Gene) POLB
Cytarabine {u} (Compound) upregulates {v} (Gene) TICAM1
Cytarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Cytarabine {u} (Compound) downregulates {v} (Gene) KIF4A
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Cytarabine (Compound) resembles Regadenoson (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease)
Cytarabine (Compound) binds POLB (Gene)
Cytarabine (Compound) upregulates TICAM1 (Gene)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Cytarabine (Compound) downregulates KIF4A (Gene)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin